Subtype
Neck Carcinoma
CI-CAN-00003406Explore in graph →
464 active trials9 approved drugs55 evidence items
- NCIt
- C6077
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003406Explore in graph →
Clinical trials
1,419 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (128)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07399158 | CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy | not yet recruiting | — | 223 | Fujian Cancer HospitalOTHER_GOV | 0 | Feb 10, 2026 | clinicaltrials |
| NCT06790589 | COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer | not yet recruiting | Phase 2 | 70 | AHS Cancer Control AlbertaOTHER | 0 | Feb 6, 2026 |
| clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05962242 | HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma(HN001) | recruiting | Phase 2 | 90 | University of VirginiaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07388758 | Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07388836 | Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 198 | Fujian Cancer HospitalOTHER_GOV | 0 | Feb 5, 2026 | clinicaltrials |
| NCT07391345 | Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal Cancer(SMART - 1_1) | recruiting | N/A | 105 | Viktoras RudzianskasOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07383246 | CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC(CAST-MTC) | recruiting | Phase 3 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07385079 | Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 412 | Sun Yat-sen UniversityOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT05894083 | A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) | recruiting | Phase 2 | 150 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06440850 | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | recruiting | Phase 2 | 21 | City of Hope Medical CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02065362 | TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376603 | IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features | recruiting | — | 169 | Qiaojuan GuoOTHER_GOV | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07373990 | Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 418 | Sun Yat-sen UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT03468218 | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | active not recruiting | Phase 2 | 36 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07101744 | Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial | recruiting | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07357571 | Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound | recruiting | — | 600 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07359586 | Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia | recruiting | — | 1,200 | Zhejiang UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT07354698 | Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery(MHI) | not yet recruiting | Phase 4 | 114 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05312710 | Safety and Efficacy of APG-157 in Head and Neck Cancer | active not recruiting | Phase 2 | 24 | Aveta Biomics, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06133374 | Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples | recruiting | — | 130 | University of CalgaryOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07343271 | Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx(DECT-CEco) | recruiting | — | 30 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07340515 | Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial | recruiting | Phase 3 | 300 | Man HuOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07328854 | 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma | recruiting | Phase 3 | 346 | Ming-Yuan ChenOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07331428 | MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC | not yet recruiting | Phase 2 | 25 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2026 | clinicaltrials |
| NCT03215719 | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | recruiting | Phase 2 | 120 | NYU Langone HealthOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT07314255 | The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma(ZL2025) | active not recruiting | — | 60 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05494190 | The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma | recruiting | N/A | 111 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05912582 | Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma | not yet recruiting | — | 60 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03734809 | NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer | active not recruiting | Phase 2 | 43 | Chinese University of Hong KongOTHER | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07303023 | Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC(INCIPT-NPC) | recruiting | Phase 3 | 462 | Fudan UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07248956 | Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma | recruiting | Phase 2 | 116 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299318 | Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer | not yet recruiting | — | 3,200 | West China HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07295561 | Salvage Surgery in Recurrent Hypopharyngeal Carcinoma: an Observational Single-institutional Study From 1998 | active not recruiting | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05340270 | PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma(NeoTurbo) | active not recruiting | Phase 2 | 150 | Guangxi Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07277764 | Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)(REDEFINE) | recruiting | Phase 2 | 23 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07188584 | Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer | recruiting | Phase 3 | 166 | Ming-Yuan ChenOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07268690 | Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07267338 | Pembrolizumab + MRGOO3 as Neoadjuvant in NPC | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04908696 | Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC) | recruiting | — | 1,000 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06623578 | Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC | recruiting | N/A | 876 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07258979 | A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | recruiting | Phase 1 / Phase 2 | 202 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04624477 | Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer | active not recruiting | — | 450 | University Health Network, TorontoOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 10, 2026source: clinicaltrials